EUVIMEDEUVIMED entdecken
Crossref

Engineering Red Blood Cells for Amplified Tumor Dual‐Gas Transfusion Therapy

Tao Li, Min Ouyang, Wei Wang, Sijin Chen, Chengxinqiao Wang, Jiahui Lai, Peixian Weng, Zhenhua Li, Yupeng Wang, Dongfang Zhou iD

Advanced Materials · 2025-09 · 37 (38)

DOI: 10.1002/adma.202503206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 04.06.2025. Verfasst von Tao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-M…. Hauptthemen laut MEDLINE: Nitric Oxide, Erythrocytes, Carbon Monoxide, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Red blood cell (RBC) transfusion therapy constitutes a vital medical intervention primarily aimed at enhancing oxygen delivery. Furthermore, RBCs possess the ability to stably bind therapeutic gas molecules such as carbon monoxide (CO) and nitric oxide (NO). As natural gas carriers, RBCs have the potential to mitigate the non‐specific gas release and biosafety issues associated with conventional gas donors, which currently hinder the clinical application of gas therapy. In this study, RBCs are innovatively engineered for amplified tumor dual‐gas transfusion therapy. The RBCs delivering CO and NO are developed using advanced nano‐ and gas‐engineering techniques. These engineered RBCs are activated by tumor cell‐specific hydrogen peroxide (H 2 O 2 ) to release gases, and it induces a cascade amplification of reactive oxygen species (ROS) and reactive nitrogen species (RNS) (ONOO − ) production through the catalytic action of the ferrous hemoglobin (HbFe 2+ ). This process disrupts glycometabolism and reshapes the tumor immunosuppressive microenvironment, thereby enhancing therapeutic efficacy. By integrating tumor cell membrane engineering, this approach enables targeted, personalized therapy and effectively suppresses metastatic tumors synergistically with α PD‐L1. Comprehensive evaluation demonstrates that engineered RBC‐based amplified tumor dual‐gas transfusion therapy exhibits excellent biosafety, and holds significant potential as a highly translatable and promising cancer treatment modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nitric OxideErythrocytesCarbon MonoxideNeoplasmsCell EngineeringAnimalsHumansMiceCell Line, TumorReactive Oxygen SpeciesHydrogen PeroxideHemoglobins

Stichwörter der Autor:innen

CO and NOengineeringglycometabolism homeostasisred blood cells (RBCs)tumor gas transfusion therapy

Substanzen

Nitric OxideCarbon MonoxideReactive Oxygen SpeciesHydrogen PeroxideHemoglobins

Autor:innen und Institutionen

  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical…
  • The Tenth Affiliated Hospital (Dongguan People's Hospital), The First School of Clinical Medicine, Southern Medical University, Dongguan, 523059, China.
  • The Seventh Affiliated Hospital, Southern Medical University, Foshan, 528244, China.
  • Key Laboratory of Mental Health of the Ministry of Education, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Southern Medical University, Guangzhou, 510515, China.

ORCID-Profile: Dongfang Zhou

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Natural Science Foundation of Guangdong Province of China
  • Guangzhou Municipal Science and Technology Bureau
  • Experimental Animal Ethics Committee of Experimental Animal Center of Southern Medical University

Zitieren

APA

Li, T., Ouyang, M., Wang, W., Chen, S., Wang, C., Lai, J., Weng, P., Li, Z., Wang, Y., & Zhou, D. (2025). Engineering Red Blood Cells for Amplified Tumor Dual‐Gas Transfusion Therapy. Advanced Materials, 37(38). https://doi.org/10.1002/adma.202503206

Vancouver

Li T, Ouyang M, Wang W, Chen S, Wang C, Lai J, et al. Engineering Red Blood Cells for Amplified Tumor Dual‐Gas Transfusion Therapy. Advanced Materials. 2025;37(38). doi:10.1002/adma.202503206

BibTeX
@article{Li2025,
  author = {Li, Tao and Ouyang, Min and Wang, Wei and Chen, Sijin and Wang, Chengxinqiao and Lai, Jiahui and Weng, Peixian and Li, Zhenhua and Wang, Yupeng and Zhou, Dongfang},
  title = {Engineering Red Blood Cells for Amplified Tumor Dual‐Gas Transfusion Therapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {38},
  doi = {10.1002/adma.202503206}
}
Kostenlos starten →